Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 8/20 | 0.47 |
| ▸ | THRB | P10828 | 2/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.47 |
| ▸ | KDR | P35968 | 3/20 | 0.35 |
| ▸ | KRAS | P01116 | 1/20 | 0.34 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | PRKDC | P78527 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4872310 | 0.88 | TGFBR1 (0.46) | TGFBR1THRBMAPK14KDR | |
| SCHEMBL4865643 | 0.87 | TGFBR1 (0.49) | TGFBR1THRBMAPK14KDR | |
| SCHEMBL411190 | 0.86 | TGFBR1 (0.62) | TGFBR1THRBMAPK14 | |
| SCHEMBL4868276 | 0.85 | TGFBR1 (0.53) | TGFBR1THRBMAPK14 | |
| SCHEMBL16296917 | 0.81 | TGFBR1 (0.49) | TGFBR1THRBMAPK14KDR | |
| SCHEMBL4863433 | 0.76 | TGFBR1 (0.58) | TGFBR1THRBMAPK14KDR | |
| SCHEMBL412729 | 0.76 | TGFBR1 (0.46) | TGFBR1THRBMAPK14 | |
| SCHEMBL4870854 | 0.76 | TGFBR1 (0.43) | TGFBR1THRBMAPK14 | |
| SCHEMBL4872949 | 0.74 | TGFBR1 (0.56) | TGFBR1THRBMAPK14KDR | |
| SCHEMBL4864349 | 0.74 | TGFBR1 (0.65) | TGFBR1THRBMAPK14KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7365066-B2 | Pyrazolopyridine derivatives as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2008-04-29 | — | — | US | claimed |
| EP-1543001-B1 | PYRAZOLOPYRIDINE DERIVATIVES AS TGF BETA SIGNAL TRANSDUCTION INHIBITORS FOR THE TREATMENT OF CANCER | LILLY CO ELI (US) | 2007-08-15 | — | — | EP | disclosed |